Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis

• Published in: Therapeutic drug monitoring Vol. 44; no. 3; p. 377
• Main Authors: Huang, Ying-Yu, Huang, Yu-Hsuan, Wu, Tsai-Hung, Loong, Che-Chuan, Hsu, Chia-Chen, Chou, Yueh-Ching, Chang, Yuh-Lih
• Format: Journal Article
• Language: English
• Published: United States 01.06.2022
• Subjects: 2-Naphthylamine; Anilides - therapeutic use; Antiviral Agents - adverse effects; Carbamates; Cyclopropanes; Cyclosporine - pharmacology; Cyclosporine - therapeutic use; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C - drug therapy; Humans; Lactams, Macrocyclic; Liver Cirrhosis - drug therapy; Macrocyclic Compounds - therapeutic use; Organ Transplantation; Proline - analogs & derivatives; Retrospective Studies; Ribavirin - therapeutic use; Ritonavir; Sulfonamides; Uracil - analogs & derivatives; Valine
• ISSN: 1536-3694
• DOI: 10.1097/FTD.0000000000000967

The clinical guidelines suggest that the dosing of cyclosporine (CsA), during combination therapy with paritaprevir/ritonavir-ombitasvir and dasabuvir (PrOD), would be only one-fifth of the pre-PrOD total daily dose to be administered once daily. However, this dosing may not be applicable to all patients depending on their clinical condition. This study focuses on the pharmacokinetic dynamics of PrOD with CsA in Asian organ transplant recipients with severe liver fibrosis or cirrhosis who undergo concurrent treatment with PrOD treatment and CsA. The efficacy and safety of PrOD treatment was also evaluated. Data from 7 patients obtained between January 2017 and September 2017 were retrospectively analyzed. Determinations of the blood concentrations of CsA were made, whether used as a single treatment or in combination therapy with PrOD. The combination regimen compared with CsA administered alone resulted in a 4.53-fold and 5.52-fold increase in the area under the concentration-time curve from time 0-12 hours (AUC0-12 h) of CsA on days 1 and 15, respectively. In addition, the maximal concentration, time to maximum concentration, and terminal phase elimination half-life (t1/2) of CsA were increased during the combined treatment of PrOD and CsA. The authors proposed reducing the CsA dosage during PrOD treatment to one-seventh of that of the pre-PrOD treatment of the total daily dose to maintain target CsA levels. All patients achieved sustained virologic responses at week 12. There were no episodes of serious adverse events or graft rejections observed. Although the combination with PrOD significantly affects the pharmacokinetics of CsA, it is effective and safe with regular monitoring of the CsA blood concentrations and appropriate CsA dose adjustment.